Melatonin in Mood Disorders and Agomelatine’s Antidepressant Efficacy

Author(s):  
Venkataramanujam Srinivasan ◽  
Edward C. Lauterbach ◽  
Samuel D. Shillcutt ◽  
Domenico De Berardis ◽  
Preetha Sharone Kuppuswamy ◽  
...  
Science ◽  
2012 ◽  
Vol 338 (6103) ◽  
pp. 72-75 ◽  
Author(s):  
Amelia J. Eisch ◽  
David Petrik

Adult-generated hippocampal neurons are required for mood control and antidepressant efficacy, raising hopes that someday we can harness the power of new neurons to treat mood disorders such as depression. However, conflicting findings from preclinical research—involving stress, depression, and neurogenesis—highlight the complexity of considering neurogenesis as a road to remission from depression. To reconcile differences in the literature, we introduce the “neurogenic interactome,” a platform from which to consider the diverse and dynamic factors regulating neurogenesis. We propose consideration of the varying perspectives—system, region, and local regulation of neurogenesis—offered by the interactome and exchange of ideas between the fields of learning and memory and mood disorder research to clarify the role of neurogenesis in the etiology and treatment of depression.


CNS Spectrums ◽  
2005 ◽  
Vol 10 (10) ◽  
pp. 808-819 ◽  
Author(s):  
Akira Kugaya ◽  
Gerard Sanacora

AbstractThe monoamine theory has implicated abnormalities in serotonin and norepinephrine in the pathophysiology of major depression and bipolar illness and contributed greatly to our understanding of mood disorders and their treatment. Nevertheless, some limitations of this model still exist that require researchers and clinicians to seek further explanation and develop novel interventions that reach beyond the confines of the monoaminergic systems. Recent studies have provided strong evidence that glutamate and other amino acid neurotransmitters are involved in the pathophysiology and treatment of mood disorders. Studies employing in vivo magnetic resonance spectroscopy have revealed altered cortical glutamate levels in depressed subjects. Consistent with a model of excessive glutamate-induced excitation in mood disorders, several antiglutamatergic agents, such as riluzole and lamotrigine, have demonstrated potential antidepressant efficacy. Glial cell abnormalities commonly associated with mood disorders may at least partly account for the impairment in glutamate action since glial cells play a primary role in synaptic glutamate removal. A hypothetical model of altered glutamatergic function in mood disorders is proposed in conjunction with potential antidepressant mechanisms of antiglutamatergic agents. Further studies elucidating the role of the glutamatergic system in the pathophysiology of mood and anxiety disorders and studies exploring the efficacy and mechanism of action of antiglutamatergic agents in these disorders, are likely to provide new targets for the development of novel antidepressant agents.


Crisis ◽  
2014 ◽  
Vol 35 (4) ◽  
pp. 278-282 ◽  
Author(s):  
Karen M. Davison ◽  
Bonnie J. Kaplan

Background: Mood disorders are associated with a high risk of suicide. Statin therapy has been implicated in this relationship. Aims: To further clarify reported associations between suicide and cholesterol in mental health conditions, we conducted an analysis of dietary, clinical, and suicidal ideation measures in community-living adults with mood disorders. Method: Data were used from a cross-sectional study of a randomly selected community-based sample (> 18 years; n = 97) with verified mood disorders. Dietary (e.g., fat, iron, vitamin intakes), clinical (e.g., current depression and mania symptoms, medications), and sociodemographic (age, sex, and income) measures were analyzed using bivariate statistics and Poisson regression with robust variance. Results: Participants were predominantly female (71.1%) with bipolar disorder (59.8%); almost one-third (28.9%) were taking lipophilic statins. The prevalence of suicidal ideation was more than 2.5 times in those taking statins, PR = 2.59, 95% CI 1.27–5.31, p < .05. The prevalence ratio for suicidal ideation was 1.10, 95% CI 1.06–1.15, p < .001, for each unit increase in mania symptom scores. No associations between suicidal ideation and dietary intake measures were identified. Conclusion: Individuals with mood disorders may be susceptible to neuropsychiatric effects of cholesterol-lowering drugs, which warrants further research.


PsycCRITIQUES ◽  
2007 ◽  
Vol 52 (33) ◽  
Author(s):  
Yasmin Nilofer Farooqi
Keyword(s):  

1995 ◽  
Author(s):  
I. S. Rosenfarb ◽  
J. Becker ◽  
A. Khan
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document